Inactive Instrument

LogicBio Therapeutics, Inc.

Equities

LOGC

US54142F1021

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CANbridge Pharmaceuticals Inc. Announces Update on Collaborations with the Umass Chan Medical School and with Logicbio Therapeutics CI
LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from S&P TMI Index CI
LogicBio Therapeutics, Inc. Announces Management Changes CI
AstraZeneca Unit Completes Acquisition of LogicBio Therapeutics MT
LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from NASDAQ Composite Index CI
Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders. CI
LogicBio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Revenue $2.7M MT
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Loss $-0.18 MT
LogicBio Therapeutics, Inc. and CANbridge Care Pharma Hong Kong Limited Enter into the Amended and Restated Exclusive Research Collaboration, License and Option Agreement CI
AstraZeneca Unit To Buy US Biotech LogicBio Therapeutics MT
ADRs End Higher, ABB and AstraZeneca Trade Actively DJ
Sector Update: Health Care Stocks Catching Up With Broader Market Gains MT
Sector Update: Health Care Stocks Mostly Higher in Afternoon Trading MT
AstraZeneca Unit to Acquire LogicBio Therapeutics; LogicBio Shares Soar MT
Sector Update: Health Care MT
LogicBio Therapeutics Shares Soar on Takeover by AstraZeneca DJ
Sector Update: Health Care Stocks Edge Higher Premarket Monday MT
Sector Update: Health Care MT
ETF Preview: ETFs, Futures Advancing Pre-Bell Ahead of Manufacturing PMI Data MT
AstraZeneca pays 660% premium for gene therapy firm LogicBio RE
US Futures Higher to Kick Off Q4 Trading MT
Top Premarket Gainers MT
AstraZeneca to Buy LogicBio Therapeutics for $68 Million DJ
AstraZeneca Unit to Acquire LogicBio Therapeutics; LogicBio Shares Soar MT
Chart LogicBio Therapeutics, Inc.
More charts
LogicBio Therapeutics, Inc. is a clinical-stage genetic medicine company. It is focused on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Its genome editing platform, GeneRide, is an approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid repair process, potentially to durable therapeutic protein expression levels. Its gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate, LB-001, for the treatment of methylmalonic acidemia (MMA) in pediatric patients. LB-001 is designed to introduce a functional copy of the methylmalonyl-CoA mutase (MUT) gene into the genome of MMA patients. It is developing LB-401 for the treatment of hereditary tyrosinemia type 1 (HT1). The Company is developing LB-301 for the treatment of Crigler-Najjar syndrome (CN).
More about the company
  1. Stock
  2. Equities
  3. Stock LogicBio Therapeutics, Inc. - Nasdaq
  4. News LogicBio Therapeutics, Inc.
  5. Chardan Capital Adjusts LogicBio Therapeutics' Price Target to $4 from $6, Keeps Buy Rating